AU4607489A - 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition - Google Patents

2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition

Info

Publication number
AU4607489A
AU4607489A AU46074/89A AU4607489A AU4607489A AU 4607489 A AU4607489 A AU 4607489A AU 46074/89 A AU46074/89 A AU 46074/89A AU 4607489 A AU4607489 A AU 4607489A AU 4607489 A AU4607489 A AU 4607489A
Authority
AU
Australia
Prior art keywords
nucleoside
composition
combination therapy
dideoxypurine
inhibitor combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU46074/89A
Other versions
AU628113B2 (en
Inventor
Mark D Erion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU4607489A publication Critical patent/AU4607489A/en
Application granted granted Critical
Publication of AU628113B2 publication Critical patent/AU628113B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: CIBA-GEIGY AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU46074/89A 1988-12-14 1989-12-08 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition Ceased AU628113B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28415388A 1988-12-14 1988-12-14
US284153 1988-12-14
US31535489A 1989-02-24 1989-02-24
US315354 1989-02-24

Publications (2)

Publication Number Publication Date
AU4607489A true AU4607489A (en) 1990-06-21
AU628113B2 AU628113B2 (en) 1992-09-10

Family

ID=26962435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46074/89A Ceased AU628113B2 (en) 1988-12-14 1989-12-08 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition

Country Status (10)

Country Link
EP (1) EP0374096B1 (en)
JP (1) JPH02204414A (en)
KR (1) KR900009083A (en)
AU (1) AU628113B2 (en)
CA (1) CA2005205A1 (en)
DE (1) DE58902899D1 (en)
DK (1) DK630589A (en)
IE (1) IE893991L (en)
IL (1) IL92587A (en)
NZ (1) NZ231718A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627188B2 (en) * 1988-06-10 1992-08-20 Regents Of The University Of Minnesota Pharmaceutical products

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2093513C1 (en) * 1989-02-27 1997-10-20 Биокрайст Фармасьютикалз Инк. 9-deazaguanine derivatives or their tautomers and pharmaceutical composition showing capability to inhibit mammal purine nucleoside phosphorylase activity
JP2619710B2 (en) * 1989-02-27 1997-06-11 日本製紙 株式会社 Method for producing 2 ', 3'-dideoxypurine nucleosides
EP0465297B1 (en) * 1990-07-04 1996-01-31 Merrell Dow Pharmaceuticals Inc. 9-Purinyl phosphonic acid derivatives
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
US5494912A (en) * 1991-06-26 1996-02-27 Merrell Pharmaceuticals Inc. 9-purinyl phosphonic acid derivitives for treating gout
CZ27399A3 (en) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
WO2005019218A1 (en) * 2003-08-26 2005-03-03 Teijin Pharma Limited Pyrrolopyrimidinethione derivative
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
DE102006017600A1 (en) * 2006-02-09 2007-08-16 Friedel, Ruthard, Dr. Use of nucleoside analogues such as purine derivatives, as medicines against viruses and cytostatic against cancer, where the nucleoside analogue has a donor group, acceptor group, and pairs only with natural base thymine
WO2014205194A1 (en) * 2013-06-22 2014-12-24 Nitor Therapeutics Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer
WO2018045045A1 (en) 2016-08-30 2018-03-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treatment using small molecule potassium-sparing diuretics and natriuretics
GB201820098D0 (en) * 2018-12-10 2019-01-23 Cambridge Entpr Ltd Methods of cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126220A (en) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc Nucleic acid component composition
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627188B2 (en) * 1988-06-10 1992-08-20 Regents Of The University Of Minnesota Pharmaceutical products

Also Published As

Publication number Publication date
DE58902899D1 (en) 1993-01-14
IE893991L (en) 1990-06-14
EP0374096B1 (en) 1992-12-02
CA2005205A1 (en) 1990-06-14
DK630589D0 (en) 1989-12-13
JPH02204414A (en) 1990-08-14
DK630589A (en) 1990-06-15
NZ231718A (en) 1992-02-25
IL92587A0 (en) 1990-08-31
EP0374096A1 (en) 1990-06-20
IL92587A (en) 1994-04-12
KR900009083A (en) 1990-07-02
AU628113B2 (en) 1992-09-10

Similar Documents

Publication Publication Date Title
AU589371B2 (en) Purine derivatives and use as therapeutic agent
AU3978689A (en) Nucleoside derivatives
AU6841990A (en) Therapeutic 6-substituted carbocyclic nucleosides
AU4636589A (en) Tissue culture antiviral processes and compositions
AU2740188A (en) N6-hydroxycycloalkyl and N6-hydroxycycloakenyl adenosine derivatives
AU2998289A (en) Skin conditioning composition
CY2018A (en) Therapeutic nucleosides
AU2992689A (en) 2',3'-dideoxy-2',2'-difluoronucleosides
AU1123388A (en) Certain adenosine 5'-carboxamide derivatives
AU4461189A (en) Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives
AU4607489A (en) 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition
AU4176089A (en) Novel 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl adenosine derivatives
AU3502789A (en) Composition and use
AU4006189A (en) Therapeutic nucleosides
AU4654289A (en) Nucleoside analogues
AU2971689A (en) Tanning compositions and their use
AU3170293A (en) Therapeutic nucleosides
AU3719489A (en) Purine derivatives
AU1318588A (en) Therapeutic nucleosides
AU4508493A (en) Therapeutic nucleosides
ZA899510B (en) 2',3'-dideoxypurine nucleoside/purine nucleoside phosphorylase inhibitor combination therapy and composition
AU3723589A (en) Therapeutic composition
AU5845594A (en) Cancerous b cell treatment using substituted nucleoside derivatives
AU5975094A (en) 1,2,4-triazinone derivatives and their use in therapy
AU2200092A (en) Therapeutic nucleosides

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired